🔗 Share this article

As America continues making unprecedented adjustments to its vaccination guidelines, an unexpected name has emerged in a surprising turn: Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccinations in the global health crisis and has concentrated on possible deaths following Covid immunization in her brief tenure at the FDA.

Proposed Shifts to Pediatric Vaccine Program

Agency leaders planned to reveal major changes to the pediatric vaccination calendar in December, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would place the US out of step with much of the international standard with little proof for public health gain. The planned update has been delayed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to present at the meeting. She was just designated interim head of the FDA’s CDER, the fifth appointee to head the office this year.

Consolidating Power at the Agency

This interim role could signify a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon reevaluating previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US so as to align more in line with Denmark's approach, a nation with nationalized medicine and a citizenry approximately the size of Wisconsin’s.

So far statements, she has persisted in emphasizing on vaccination policy – usually the responsibility of Dr. Prasad, head of the FDA’s CBER – instead of drug regulation.

Doubts Over Expertise

Høeg has no obvious experience in medication creation, regulation or management, which has been typical for former heads of the CBER. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She appears not to have the necessary background” for running the drug-regulation department, remarked Jonathan Howard. “She’s never run a clinical trial. She has no expertise in running a large organization. She has no expertise in drug approvals.”

Past heads of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that prior appointees who headed CBER have had.”

CDER has an enormous portfolio at the FDA, she stated.

“The public just focuses on the new drug program, but the generic program approves numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and so forth, and every single one have to be looked after,” she noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial management component to the position, which supervises more than 5,000 personnel. “It’s a huge administrative position, if you execute it properly,” Woodcock added.

Agency Reaction and Controversial Policies

In response to questions about Dr. Høeg's fitness for the role and whether this assignment signifies greater collaboration among agency officials on immunizations, a press secretary said that the “questions rely on flawed premises”.

“This background is consistent with the responsibilities of her position,” the representative said, citing the months Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s controversial fast-track approval initiative, a controversial expedited drug-approval program that allegedly concerned her predecessors. “By what process are these drugs being selected for this voucher program? Who makes the calls?” Howard said. “There is a lot of secrecy occurring at the agency right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards less stringent regulations of pharmaceuticals, except for immunizations.”

Documented Track Record on Immunizations

With vaccines, Høeg has a more established, if concerning, track record, some experts observe. She published a research paper using unverified public submissions to determine the rate of heart inflammation following COVID-19 vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the new administration featured changing guidelines for new vaccines and discontinuing “optional” immunizations, she said after the election on a online show. At the agency, Høeg has according to sources floated the idea of excluding teenage boys from obtaining Covid vaccines.

“She is an all-around true believer who begins with her preconceived notions and works backwards to fit the science in a extremely disingenuous, untruthful fashion,” Howard said.

Consolidating Power and a “Push for Payback”

Høeg became part of other contrarians, {like|